All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @agwilliamtong on TikTok · 57s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @agwilliamtong's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00just to be clear, four branded drugs and that's it.
  2. 0:04And you must be under the carrots and poison of the doctor.
  3. 0:07And sometimes you hear, well, compounding is okay.
  4. 0:10There's a generic form, there's research grade, none of that.
  5. 0:14None of that is safe.
  6. 0:16Which is why in the obviously attorney general, we've gone after meds files here
  7. 0:20and to get that advertised, that they can dispense GLP1s
  8. 0:25or generic forms of wagovi or ozepic or vajaro or Zepbound.
  9. 0:31Or they have some research grade form that's okay for you.
  10. 0:34No, that's not okay, which is why we've sent out
  11. 0:37season-desis letters to meds files for what's Connecticut.
  12. 0:40We've taken action against a number of meds files
  13. 0:43and we've gone after major online retailers.
  14. 0:46For me, it's like a gamble whack-a-mole.
  15. 0:48As soon as you go after once, somebody else pops up and is doing the same thing.
  16. 0:53We need comprehensive federal protection and relief.

@agwilliamtong's GLP-1 compounding claims, fact-checked

agwilliamtong

TikTok creator

10.8K viewsWatch on TikTok →

Quick answer

No FDA-approved generic versions of semaglutide or tirzepatide exist as of mid-2025. The four approved branded GLP-1 injectable products for weight management or type 2 diabetes are Ozempic, Wegovy, Mounjaro, and Zepbound. Compounded semaglutide from 503B outsourcing facilities operated legally during the FDA shortage period, but FDA's 2025 shortage resolution declaration means most compounding pathways are being closed, pending ongoing litigation.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion
Start provider reviewBrowse video library

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @agwilliamtong's GLP-1 compounding claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Video claim decision path

Turn the claim into a safer next question

Direct answer

@agwilliamtong's GLP-1 compounding claims, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Start the provider review

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Helpful context before the funnel

Review method

See how FormBlends checks viral health claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@agwilliamtong's GLP-1 compounding claims, fact-checked" from agwilliamtong. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: No FDA-approved generic versions of semaglutide or tirzepatide exist as of mid-2025.

The reason this review is not generic is the source wording and the canonical claim label "glp1 i stood alongside senator blumenthal today to urge the fda t." In this clip, the useful excerpt is: "just to be clear, four branded drugs and that's it." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

FDA declared the semaglutide shortage resolved in early 2025, which triggered a legal battle with compounding pharmacies.
People who land here are usually trying to understand whether the GLP-1 social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

No FDA-approved generic versions of semaglutide or tirzepatide exist as of mid-2025.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • No FDA-approved generic versions of semaglutide or tirzepatide exist as of mid-2025. The four approved branded GLP-1 injectable products for weight management or type 2 diabetes are Ozempic, Wegovy, Mounjaro, and Zepbound. Compounded semaglutide from 503B outsourcing facilities operated legally during the FDA shortage period, but FDA's 2025 shortage resolution declaration means most compounding pathways are being closed, pending ongoing litigation.
  • No FDA-approved generic semaglutide or tirzepatide injectable exists as of mid-2025. Any product labeled as one is factually mislabeled.
  • FDA declared the semaglutide shortage resolved in early 2025, which triggered a legal battle with compounding pharmacies. The outcome of those cases will affect compounded GLP-1 availability.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • No FDA-approved generic semaglutide or tirzepatide injectable exists as of mid-2025. Any product labeled as one is factually mislabeled.
  • FDA declared the semaglutide shortage resolved in early 2025, which triggered a legal battle with compounding pharmacies. The outcome of those cases will affect compounded GLP-1 availability.
  • 503B outsourcing facilities operate under CGMP standards and FDA inspections. Equating them with unregulated research chemical sellers is not accurate, though compounded drugs are not FDA-approved for safety or efficacy.
  • Salcido et al. (2024, Obesity Medicine) documented real adverse events linked to unverified GLP-1 products purchased outside regulated pharmacy channels, including dosing errors.
  • "Research grade" peptides sold online carry contamination and dosing risks and are not intended for human use. FDA has issued explicit warnings on these products.
  • If you use a telehealth platform for GLP-1 access, ask whether the dispensing pharmacy is 503A or 503B accredited. That distinction has real regulatory and safety implications.
  • Four branded drugs cover the main FDA-approved GLP-1 options for weight management and type 2 diabetes: Ozempic, Wegovy, Mounjaro, and Zepbound. Saxenda (liraglutide) is also FDA-approved for obesity.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @agwilliamtong actually say?

The creator, appearing to be a Connecticut official speaking alongside Senator Blumenthal, made two core claims: that there are exactly four legitimate branded GLP-1 drugs on the market, and that compounded, generic, and "research grade" versions are categorically unsafe. He said, "none of that is safe," referring to compounding, generics, and research-grade formulations. He also described enforcement actions his office has taken against pharmacies and online retailers advertising these alternatives.

He framed this as a consumer protection issue, calling it a "gamble whack-a-mole" problem where enforcement can't keep pace with the number of actors selling questionable products. His call to action was federal-level intervention, not just state enforcement.

Does the science back this up?

Partially. The claim that no FDA-approved generic GLP-1 injectable exists is accurate as of mid-2025. The claim that all compounded versions are automatically unsafe is an overstatement, though the risk landscape for unregulated compounded products is real and documented.

The FDA's own shortage list drove a significant expansion of compounded semaglutide. When a drug is on the FDA's drug shortage list, Section 503A and 503B pharmacies are legally permitted to compound versions of it. Semaglutide was on that list, which is why compounding proliferated. The FDA has since moved to remove semaglutide from the shortage list, triggering legal battles from compounding pharmacies (Alliance for Pharmacy Compounding v. FDA, 2025). The FDA confirmed in early 2025 that the shortage had resolved, and that compounded semaglutide from 503A pharmacies would no longer be permitted.

The safety concern he raises is legitimate in a specific sense: products sold as "research grade" or through unregulated online retailers have no quality assurance, no sterility testing oversight, and no pharmaceutical-grade manufacturing standards. Salcido et al. (2024, Obesity Medicine) documented adverse events linked to unverified GLP-1 products, including dosing errors and contamination concerns. That is a real problem. But equating that with all compounded GLP-1s from licensed 503B facilities is a stretch.

What did they get wrong (or right)?

He got the core consumer warning right: there are no generic GLP-1 injectables, and anyone claiming to sell one is misrepresenting their product. That's accurate and worth saying loudly.

Where he oversimplifies is the blanket claim that "compounding is okay" is a lie. Licensed 503B outsourcing facilities operate under FDA oversight, including Current Good Manufacturing Practice (CGMP) standards. A compounded semaglutide from a 503B facility is not the same as a vial sold by a research chemical website. Conflating those two things is misleading, even if the intent is protective.

He also doesn't mention that the ongoing legal fight over FDA's shortage determination is live and unresolved. Several compounding pharmacies are still operating under court injunctions as of 2025. Saying "none of that is safe" without that nuance overstates the certainty of the regulatory picture.

The enforcement framing is credible. Connecticut's AG office has documented action against medspa and online retailers. That's verifiable public record, and it's a problem worth federal attention.

What should you actually know?

If you're considering a GLP-1 medication, the regulatory status of where it comes from matters more than the marketing. Here's what the evidence actually supports.

  • There are no FDA-approved generic semaglutide or tirzepatide injectables. Any product marketed as a "generic Ozempic" or "generic Wegovy" is factually mislabeled.
  • Compounded semaglutide from licensed 503B outsourcing facilities is not automatically unsafe, but it is not equivalent to the branded drug, and FDA does not review compounded formulations for efficacy or safety before they reach patients.
  • "Research grade" peptides sold online are manufactured with no pharmaceutical oversight whatsoever. These are not intended for human use and carry genuine contamination and dosing risks.
  • The FDA moved to end compounded semaglutide in early 2025 after declaring the shortage resolved. Legal challenges are ongoing, so the availability of compounded versions through telehealth may change.
  • If you're prescribed a compounded GLP-1 through a legitimate telehealth platform, ask directly whether the pharmacy is 503A or 503B, and whether it is PCAB-accredited. Those distinctions matter.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

agwilliamtong · TikTok creator

10.8K views on this video

I stood alongside Senator Blumenthal today to urge the fda to take comprehensive action to protect people from unsafe compound weight loss drugs. There are no generic GLP-1 injections. Anyone adverti

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about no fda-approved generic semaglutide?

No FDA-approved generic semaglutide or tirzepatide injectable exists as of mid-2025. Any product labeled as one is factually mislabeled.

What does the video say about fda declared the semaglutide shortage resolved in early 2025,?

FDA declared the semaglutide shortage resolved in early 2025, which triggered a legal battle with compounding pharmacies. The outcome of those cases will affect compounded GLP-1 availability.

What does the video say about 503b outsourcing facilities operate under cgmp standards?

503B outsourcing facilities operate under CGMP standards and FDA inspections. Equating them with unregulated research chemical sellers is not accurate, though compounded drugs are not FDA-approved for safety or efficacy.

What does the video say about salcido et al. (2024, obesity medicine) documented real adverse events?

Salcido et al. (2024, Obesity Medicine) documented real adverse events linked to unverified GLP-1 products purchased outside regulated pharmacy channels, including dosing errors.

What does the video say about "research grade" peptides sold online carry contamination?

"Research grade" peptides sold online carry contamination and dosing risks and are not intended for human use. FDA has issued explicit warnings on these products.

What does the video say about if you use a telehealth platform for glp-1 access, ask?

If you use a telehealth platform for GLP-1 access, ask whether the dispensing pharmacy is 503A or 503B accredited. That distinction has real regulatory and safety implications.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by agwilliamtong, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.